“We are trying to decide if we will build or buy something for risk-based monitoring”, or some variation of it, is something we hear at nearly every meeting with a prospective customer of TRI’s OPRA. With everything from email to infrastructure to applications frequently being outsourced today, I find it curious that so many companies are interested in making an investment in building a custom technology solution.
I am aware of several products in the RBM space, each would seem to serve a need depending upon your perspective (whether you are looking for a statistical, operational or intelligence tool). Building any application is a huge investment and companies rarely build their own EDC, CTMS, or document management system. What is it about RBM that is driving the build/buy decision?
Please join the discussion in Risk-Based Monitoring in Clinical Trials group on LinkedIn: